Beta Cell Regeneration via DYRK1A and GLP1R Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to induce therapeutically relevant rates of human beta cell proliferation and are associated with off-target effects, limiting their efficacy in treating diabetes.
Innovation Solution
Combining a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor with a glucagon-like peptide-1 receptor (GLP1R) agonist to synergistically enhance human beta cell proliferation, achieving rates up to 5-6%/day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If GLP1R agonists are used to induce beta cell proliferation, then beta cell replication is activated in rodent models, but they fail to activate beta cell replication in adult human islets
Solution Approach 1:
The patent combines GLP1R agonist therapy with DYRK1A inhibition to achieve synergistic beta cell proliferation. The combination targets multiple pathways simultaneously: GLP1R activation provides metabolic benefits and modest proliferation, while DYRK1A inhibition removes the phosphorylation brake on beta cell replication, together achieving robust human beta cell expansion that neither agent achieves alone.
Solution Approach 2:
The patent changes the biochemical parameter of DYRK1A kinase activity through pharmacological inhibition. By reducing DYRK1A-mediated phosphorylation of key substrates including NFATc3, the therapy shifts the cellular state from quiescence to proliferation in human beta cells, overcoming the species-specific limitation of GLP1R agonists.
2Productivity
If DYRK1A inhibitors are used to increase beta cell proliferation, then proliferation rates increase, but off-target effects and insufficient beta cell mass regeneration occur
Solution Approach 1:
The patent uses GLP1R agonist as an intermediary that provides multiple beneficial effects including metabolic regulation, beta cell protection, and modest proliferation stimulation. When combined with DYRK1A inhibition, the GLP1R agonist acts as a mediator that enhances the specific proliferative effect while providing protective and metabolic benefits that reduce off-target harmful effects.
Solution Approach 2:
The patent creates a composite therapeutic approach combining two distinct mechanisms: GLP1R agonism and DYRK1A inhibition. This composite therapy leverages the synergistic interaction between the two agents to achieve superior beta cell mass regeneration with an improved safety profile compared to either monotherapy.
3Quantity of substance
If adult human beta cells are stimulated to replicate, then beta cell mass may increase, but human beta cells fail to replicate at therapeutically relevant rates
Solution Approach 1:
The patent converts the harmful effect of DYRK1A-mediated phosphorylation (which acts as a brake on proliferation) into a benefit by pharmacologically inhibiting DYRK1A. This inhibition removes the phosphorylation barrier, allowing beta cells to respond robustly to mitogenic stimuli and achieve therapeutically relevant replication rates and mass expansion.
Data Source
AI summary
Disclosed herein are methods of increasing cell proliferation in a population of pancreatic beta cells. Also disclosed are methods of treating a subject for a condition associated with insufficient insulin secretion. Also disclosed is a composition comprising a DYRK1A inhibitor and a GLP1R agonist. The disclosure further describes a method of regenerating pancreatic beta cells in a transplant patient.